A preventive pancreatic cancer vaccine triggered immune responses in 90% of high-risk participants in its first human trial — a remarkable result for one of medicine's most lethal cancers. Johns Hopkins researchers tested mKRAS-VAX on 20 people with inherited pancreatic cancer risk who hadn't yet developed tumors, targeting six common KRAS mutations that drive over 90% of pancreatic ductal adenocarcinomas. Four injections over 13 weeks delivered measurable...